Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360º synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of PNH
3.2.1.2 Improved healthcare infrastructure
3.2.1.3 Advancement in treatment options
3.2.1.4 Increasing R&D activities to introduce new therapies for PNH treatment
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory approvals
3.2.2.2 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Million)
5.1 Key trends
5.2 Complement inhibitors
5.3 Iron therapy
5.4 Immunosuppressants drugs
5.5 Bone marrow transplantation
5.6 Other treatment types
Chapter 6 Market Estimates and Forecast, By Route of administration, 2021 - 2032 ($ Million)
6.1 Key trends
6.2 Oral
6.3 Parenteral
Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Million)
7.1 Key trends
7.2 Pediatric
7.3 Adult
Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Million)
8.1 Key trends
8.2 Hospitals
8.3 Specialty clinics
8.4 Homecare settings
8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Amgen Inc.
10.2 Apellis Pharmaceuticals, Inc.
10.3 AstraZeneca Plc
10.4 Children’s National Hospital
10.5 F. Hoffmann-La Roche Ltd.
10.6 Memorial Sloan Kettering Cancer Center
10.7 Novartis AG
10.8 Pfizer, Inc.
10.9 Regeneron Pharmaceuticals Inc.
10.10 Teva Pharmaceuticals Industries Ltd.
10.11 UCLA Health
10.12 University of Rochester Medical Center
